Agalsidase beta biosimilar (ISU Abxis/GC Pharma)

阿加糖酶β生物类似药 (ISU Abxis/GC Pharma）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAgalsidase beta biosimilar (ISU Abxis/GC Pharma)
Drug Alias NameAgalsidasa beta (ISU Abxis/GC Pharma)阿加糖酶β生物仿制药 (ISU Abxis/GC Pharma）Agalsidasum beta (ISU Abxis/GC Pharma)Agalsidase β (ISU Abxis/GC Pharma)Agalsidase beta (ISU Abxis/GC Pharma) +[7] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzymeBiologics > Biosimilar
Mechanisms of Actionglycosphingolipid hydrolysis activatorsglobotriaosylceramide (GL-3) hydrolysisα-Galactosidase replacements
TargetsGlycosphingolipid
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsFabry Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2014/01/01
Country/TerritoryPhilippinesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIsu Abxis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIsu Abxis Co LtdPetrovax Pharma
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeA16AB04
Related LinksN/A